| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 1,200 | 410 | 0 | 0 | 0 |
| Sales Growth | +192.68% | unch | unch | unch | unch |
| Net Income | -10,040 | -40,380 | -25,380 | -20,940 | -1,930 |
| Net Income Growth | +75.14% | -59.10% | -21.20% | -984.97% | -112.82% |
Emmis Acquisition Corp Cl A (EMIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Emisphere Technologies is a biopharmaceutical company focused on the development of a family of oral heparin products; the application of proprietary synthetic chemical compounds to serve as ``carriers`` to facilitate the transport of therapeutic macromolecules and other compounds across biological membranes; and the development, in conjunction with the company's pharmaceutical collaborators, of oral formulations of selected therapeutic macromolecules.
Fiscal Year End Date: 12/31